Introduction: The aim of this study was to report the clinical features, management, and outcome of two cases of complete hydatidiform mole with a coexisting viable fetus and to review the literature.
Case Reports: In this article, we report on the well-documented follow-up of two cases of twin pregnancies with complete hydatidiform mole and a normal fetus. Genetic amniocentesis showed normal fetal karyotype in both of two cases. In the first case, a live male infant was delivered by a cesarean section because of severe maternal bleeding at 29 weeks of gestation. In the second case, termination of pregnancy was performed due to early onset of severe preeclampsia and vaginal hemorrhage.
Conclusion: The chances of a live birth have been estimated between 30 and 35% and the risk of persistent trophoblastic disease is similar to singleton molar pregnancies in complete mole with coexisting fetus pregnancy. Therefore, in these pregnancies, expectant management instead of termination of pregnancy can be suggested.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00404-008-0737-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Serum hCG levels in the prediction of molar pregnancy below 11 weeks of gestational age.
Rev Assoc Med Bras (1992)
December 2024
Universidade Federal de São Paulo, Escola Paulista de Medicina, Department of Obstetrics - São Paulo (SP), Brazil.
Objective: The aim of this study was to evaluate the serum hCG level in the differential diagnosis between non-molar miscarriage and complete hydatidiform mole in<11 weeks gestation.
Methods: This was a retrospective collaborative cohort study. This study included women with gestational age<11 weeks, with ultrasound evidence of failed pregnancy and available serum hCG pre-uterine evacuation, divided into two groups: the non-molar miscarriage group and the complete hydatidiform mole group.
Outcomes of patients registered with the Queensland Trophoblast Centre diagnosed with gestational trophoblastic neoplasia who develop resistance to chemotherapy.
Aust N Z J Obstet Gynaecol
December 2024
Queensland Trophoblast Centre, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Objectives: To audit outcomes of patients registered in the Queensland Trophoblast Centre (QTC) database who develop resistance to primary chemotherapy. To determine any risk factors that may predict first-line chemotherapy resistance in patients diagnosed with gestational trophoblastic neoplasia (GTN).
Methods: Patients within the QTC who were diagnosed with GTN between January 2012 and December 2020 were reviewed.
Gestational trophoblastic neoplasm: Patient outcomes and clinical pearls from a multidisciplinary referral center.
Gynecol Oncol
December 2024
Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States; Department of Medicine, Weill Cornell Medical College, New York, NY, United States.
Objectives: To describe clinical outcomes and pearls for patients with gestational trophoblastic neoplasm (GTN).
Methods: Patients with GTN treated at a referral center from 1/2006 to 12/2022 were included. Clinical characteristics, World Health Organization risk score (low-risk 0-6, high-risk ≥7), and treatments/outcomes were evaluated using summary statistics, stratified by initial treatment at a referral center versus locally.
Vaginal metastasis in gestational trophoblastic neoplasia: Experience from Sheffield trophoblastic disease Centre and recommendations for management.
Eur J Obstet Gynecol Reprod Biol
November 2024
Sheffield Trophoblastic Disease Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Introduction: Gestational trophoblastic neoplasia (GTN) is rare in the UK, with an estimated incidence of one in 50,000 live births. Cases of vaginal metastasis are even rarer, with only eight case series reporting 187 cases over the past 40 years. Management recommendations in the literature are scarce despite the potential risk of massive, potentially life-threatening vaginal haemorrhage.
View Article and Find Full Text PDFDiagnosis of hydatidiform moles using and : A retrospective study.
Int J Reprod Biomed
September 2024
Maternal-Fetal Medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Article Synopsis
- The study utilized chromogenic in situ hybridization and immunohistochemistry to distinguish between partial hydatidiform mole (PHM), complete hydatidiform mole (CHM), and non-molar hydropic abortion (HA) in products of conception (POCs).
- A retrospective analysis of 44 POCs revealed a high accuracy rate, with Kappa agreement at 95.4%, effective in diagnosing the conditions and differentiating between triploid and diploid specimens.
- The findings suggest these methods could serve as reliable surrogate markers for chromosomal ploidy, prompting future research on fresh specimens and comparing results with other diagnostic techniques like flow cytometry and fluorescence in situ hybridization.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!